English: Recent Actions of the US FDA Dr. David Asher, Chief Laboratory of Bacterial, Parasitic and Unconventional Agents Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research and Review CBER FDA Rockville, Maryland, USA 11:05 Presentation Update on FDA Risk Assessment Activities for potential vCJD Risk for Blood and Plasma-derived Products Dr. Steve Anderson, A/ Director Office of Biostatistics & Epidemiology FDA - Center for Biologics Evaluation and Research Rockville, MD 11:25 Presentation Risk of Banked Tissues Dr. Albert Farrugia, Professor and Head Blood and Tissues Unit Office of Devices, Blood and Tissues Therapeutic Goods Administration ACT, Australia 11:45 Presentation EUSTITE - WHO project Dr. Luc Noel, Coordinator 'Clinical Procedures' CPR/EHT/HTP Essential Health Technologies World Health Organization-HQ Geneva, Switzerland 12:05 Working Lunch 13:05 Presentation Looking Forward to More Diseases Surrounded by Uncertainty Dr. Paul Gully World Health Organization-HQ Geneva, Switzerland 13:35 Presentation Determining PrPSc/RES Log Reduction Value using Western Blot Assay Dr. Kang Cai, Section Head TSE Research and Validation The Pathogen Safety Department Talecris Biotherapeutics 13:55 Presentation The State of the Assessment of Abnormal Prion Prevalence Dr. Akram Zaman on behalf of Dr. Noel Gill CJD Section Health Protection Agency Centre for Infections London, UK 14:15 Health Break 14:40 Presentation Chagas Disease and the Blood Supply Dr. Margaret Fearon, Executive Medical Director Medical Microbiology Canadian Blood Services Toronto, ON 15:00 Presentation PART I - Structured Expert Elicitation and its Role in Policy and Decision Making Dr. Willy Aspinall Aspinall & Associates Beaconsfiled, UK 16:30 Panel Discussion / Closing Remarks 17:20 End of Session 18:30 End of the day Activity organize by:
French: Récentes intervention de la Food and Drug Administration des États-Unis Dr. David Asher, Chef Laboratory of Bacterial, Parasitic and Unconventional Agents Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research and Review, CBER FDA Rockville, Maryland, US 11:05 Présentation Mise à jour des activités d’évaluation des risques de la Food and Drug Administration en matière de risque potentiel de la vMCJ de produits sanguins et dérivés du plasma Dr. Steve Anderson, Directeur intérimaire Office of Biostatistics & Epidemiology Center for Biologics Evaluation and Research Food and Drug Administration Rockville, Maryland, US 11:25 Présentation Le risque des tissus en banque Dr. Albert Farrugia, Professeur et chef Blood and Tissues Unit Office of Devices, Blood and Tissues Therapeutic Goods Administration Woden, ACT, Australie 11:45 Présentation Vigilance et surveillance : Mise à jour du composant de vigilance et surveillance EUSTITE Dr. Luc Noel, Coordinateurr Procédures cliniques (RPC/ESE) Organisation mondiale de la santé Genève, Suisse 12:05 Déjeuner de travail 13:05 Présentation Les perspectives de plus de maladies entourées d’incertitude Dr. Paul Gully, Chef de projet Programme d’influenza mondiale Département des interventions en cas d’épidémie et d’alerte pandémique Sécurité et environnement Organisation mondiale de la santé Genève, Suisse 13:35 Présentation Détermination de la valeur de réduction PrPSc/RES log à l’aide d’essais par transfert Western Dr. Kang Cai, Chef de section Transmissible Spongiform Encephalopathy Research and Validation Pathogen Safety Department Talecris Biotherapeutics Research Triangle Park, North Carolina, US 13:55 Présentation L'état de l'évaluation de la prévalence des prions anormaux au Royaume-Uni Dr. Akram Zaman au nom du Dr. Noel Gill CJD Section Health Protection Agency Centre for Infections Londres, R.-U. 14:15 Pause-santé 14:40 Présentation La maladie de Chagas et les banques de sang : la réponse de la Société canadienne du sang Dre.